ArticleJournal of the American Heart Association2025
Myocarditis-Associated Cardiogenic Shock: A Nationwide Multicenter Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data on the management of myocarditis-associated cardiogenic shock. The aim of this study was to assess the clinical outcomes of patients with myocarditis-associated cardiogenic shock.
methodsIn this retrospective study using the Vizient Clinical Data Base, patients aged ≥18 years admitted with cardiogenic shock during 2015 through 2023 across the United States were stratified by myocarditis status. We assessed in-hospital death by augmented inverse probability weighting, accounting for demographics, comorbidities, critical care therapies, and hospital characteristics.
resultsA total of 621 695 patients with cardiogenic shock were included. Patients with myocarditis (n=2925; 0.5%) were younger (49.9 versus 65.2 years), more likely to be women (45.9% versus 36.7%), and had a lower Charlson comorbidity index (3.6 versus 4.4) but higher rates of cancer (13.5% versus 7.5%) and rheumatic disease (8.3% versus 3.4%) (all
conclusionsMyocarditis-associated cardiogenic shock is uncommon yet represents a critically ill population with a higher adjusted in-hospital mortality rate. Future work investigating therapies for this unique patient population is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.